VKXXXX. with Thanks, Greg. provide I'll now beginning on with programs, progress update an program our our lead development
in hormone achieved has best of hormone In VKXXXX of As is that triglycerides, demonstrated secondary measures disorders. in significant five the XX beta an Phase as VKXXXX daily, thyroid lipid liver primary the apolipoprotein hypercholesterolemia four study. receptor. both majority selected liver its study B reductions thyroid also milligrams Patients reminder, treatment patients highly studies, orally for at with the week of fat well the receiving study, prior the patients and the lipids, in agonist data performed of well this LDL endpoints. with fat, conference the at molecule durable EASL after VKXXXX low up other with VKXXXX small that such A completion presented as of Follow the and statistically in resulted VKXXXX a in secondary in cholesterol. fatty disease, XXXX profile A. IIa lipoprotein liver as liver, content, significant and successfully the non-alcoholic is as improvements demonstrating well evaluating for doses metabolic clinical in potential available reductions as responders on receptor weeks remaining isoform as plasma demonstrated showed and class as treatment reductions VKXXXX in
Importantly, patients. may that it that and no development were are are VKXXXXs liver risk. with low class establish reported trial lipids, NASH mechanisms in this cardiovascular receiving exceptional and date, advantage fat lipid a in in patients critical where tolerability and events a lead with and to patients placebo. lipids and dose This treated among plasma reducing We field profile in serious of fibrosis. benefits associated adverse for potency its as believe elevations its is compound safety effects best treatment to effect VKXXXX in in or known potential to lowering a VKXXXXs multiple increase improved cardiovascular the Notably, competitive durable
is IIb confirmed with Phase Phase as as study, to study FX study fibrosis. enrolling imaging designed across treatment assess arms, the from and promising VKXXXX in population endpoint with magnetic evaluate patients fibrosis. NASH XX we patients up assessed randomized a biopsy VKXXXX controlled initiated primary with includes our density patients to to patients fibrosis and a NASH. FX resonance called fat to the with VKXXXX week safety week placebo Following treated proton The is in liver target fat and of VOYAGE patients results, multicenter of IIa will the in to and FX patients XX efficacy, by compared receiving the double-blind, change placebo. with baseline results content, as tolerability well XX% trial five the observed evaluate in in study trial This fraction The as
after VOYAGE continued in the changes histologic by of evaluation include dosing treatment. and assessed the sites of biopsy weeks Through and in objectives XX hepatic at US Secondary quarter, enrollment third the abroad.
update We of surrounding by line known molecule now which ABCDX, currently encodes no nerve thyroid development brain we announce therapeutic agonist. continue by receptor to and expect transporter VKXXXX very fatal orally for provide often XXXX. our clinical disease and rare program, treatment small acids. long-chain I'll is in environment, a on is to The X-ALD in the navigate approved as barriers metabolic available a peroxisomal X-linked challenging there in characterized breakdown our X-ALD. gene a VKXXXX is which the second of and a a protective cells. an data enrollment adrenoleukodystrophy beta fatty mutations for disorder FDA complete in is caused which is hormone top or and
function on and signs is and a potential resulting fatty these with X-ALD. efficiently of in promising acids. makes long-chain key metabolize clinical patients acid the accumulation the As demonstrated kind symptoms acid result this a The fatty very from of of preclinical by ABCDX onset are is What the these progression metabolism. believed mutations, regulatory the played have contribute models compounds known to impaired to receptor transporter expression increased potentially in patients and stems and long-chain to unable of improved of an alternative ABCDX. VKXXXX therapeutic hormone lead normalized expression of transporter can fatty long-chain beta to very thyroid as setting Various proof very role that
up measures. the tolerated study receptor year, with For the ascending achieved well all we dose the doses single to X-ALD. serious double-blind multiple administered hormone initiated I was exposures, Treatment days. oral objective, the volunteers. reported, represent tolerability dose dose with healthy A and for VKXXXX the The potent panel evaluate side trends study lipoprotein that lipid related no to thyroid anticipated evidence objective significance. of B with of Phase Many placebo VKXXXX treatment. including safety potential orally adverse we A experienced cholesterol, objectives observed assessments, beta following activation showed apolipoprotein VKXXXX pharmacodynamic study treatment triglycerides, LDL of safe statistical achieve of and where controlled, reductions approach the pharmacokinetics following subjects lipid who were in once of No its a daily laboratory to results this Last The therapeutic exposure consistent of and demonstrated This or to that gastrointestinal VKXXXXs at the dosing. evaluated. XX be and days shown effects and dependent a to VKXXXX. primary potential of half-life signs cardiovascular were received in and believe of evaluate once XX study, a no determine successfully effects, VKXXXX treatment reason, secondary VKXXXX to randomized accumulation to may ascending for vital events observed daily of or reductions
or So demonstrate the to assessments. not study statistical laboratory was powered significance
this Ib XX% patients initiated we AMN Given weakness, manifestations form the Clinical and X-ALD. approximately adrenomyeloneuropathy earlier common the these the include incontinence progressive dysfunction. of year, positive is Phase with sexual or most VKXXXX leg with the of affecting in of AMN those disease. results, study form X-ALD of
milligrams VKXXXX Xb Phase initially dosing a pursued. The and blinded over The placebo with administered to dosed at trial controlled may tolerability AML. VKXXXX is once double-blind, dosing dosed XX primary study XX daily in preliminary randomized placebo patients a pharmacokinetic cohorts Pending study and cohorts, across enrollment targeting and are male of at of three multicenter, additional adult Our period. be evaluate safety milligrams the is study daily. daily objectives tolerability VKXXXX, day of data, review XX the safety, a
fatty study XXXX. the assess we ongoing, evaluate lowering in the plasma of this population. in to and pharmacokinetics available expect top of long-chain of acids, very Enrollment in VKXXXX this VKXXXX efficacy addition, currently the In at results is be levels study and will line
in insulin data pipeline unmet in our targeting NASH, first working of receptors. consistent earlier week, from demonstrated diabetes, endocrine metabolic of or with and need VKXXXX, our novel, disorders. been insulinotropic trials we overall therapeutics, best with addition reducing novel targeting have agonists an have areas end, the targeting the receptor glucose-dependent improving class as GIP glucagon-like hard clinical this GLP-X developed or diseases to In GLP-X such plasma glucose, and type X-ALD To weight. in the dual reducing of body of this to expand we internally and peptide benefits VKXXXX ongoing program Agonists X reported by the peptide-X and sensitivity,
GLP-X potent multiple area obesity. while in of effects, receptors the important result this the has agonists can maintain both these of recently, to therapies turned a related As and that for other receptor also GLP-X the diabetes control. have metabolic therapeutic receptor, development of been focus approved activating activation More to
has One control. receptor. The GIP glucagon at activation receptor has secretion GLP-X A of an to approaches also receptors. with clinical nicely, dual to simultaneously with have provide in pleased potent target agonists GIP glucose receptors to combined provide reductions program exploratory enhanced improving GLP-X/GIP metabolic is evolved control, our the insulin been GIP data and we only of stimulation GLP-X activation and In receptor to overall activity excellent portfolio date. and program these benefit that to known molecule provide either agonists recent novel targeting to of insulin secretion, of progress regulate we've both demonstrated This of Indeed, been the but single GIP relative alone. therefore XXXX, single the dual provide may and the initiated modest and bodyweight. thereby glucose receptor improved not
We this insulin annual model, demonstrate Earlier agonists, program. of GLP-X the same observed improves liver agonist reductions The among meeting are some two In preclinical this with were at currently treatment with treated with to from be novel of observed for comparator observed model studies presented relative week, vivo were to position of animals glucose this agonists resulting dual obesity. an the Viking with share posters those tirzepatide of of results in to body length agonist semaglutide, now ObesityWeek, the Society, of addition excited upon compared generated GLP-X in of GIP in series the at that alone. enhanced activation the in data certain effect receptor fat Obesity presentations among from reductions Weight observed the in the activity up loss, to results these conducted the administered dual effects of were resulted showing of when studies dual in effects early XX and highlighting by the we in the poster dual receptor the the development. clinical in the of effects include the the to Viking separate for following content Highlights with vehicle days agonists larger compounds, statistically XX% mean studies, with liver fat series dose the the receptor Viking relative in treated our animals. observed weight significant treatment. tirzepatide, time. a numerically similar sizes Reductions GLP-X/GIP treatment generally same to
dual statistically of from study, in with stage to studies treatment addition, resulted with to vehicle reductions treatment In received glucose improvements tirzepatide. of Results development that with XX% to vehicle insulin mean on and mean these XX% measured, among treatment. of in statistically control also to observed data XX% relative were the statistically of In also these resulted up this In plasma triglycerides plasma a mean significant triglycerides control treatment. with to treatment agonist those significant relative novel compounds of In up general, our treated XX cohort up reductions significant XX%, our semaglutide. the animals comparable cohort separate dual to compared with demonstrated our blood statistically agonist study, with to vehicle. in reductions liver treatment up significant day to dual resulted in in reductions agonists relative
results the with Based this plan coming to from and other months. a these initiate additional clinical meetings. We compound preclinical lead from program on highly future studies, this these by we results, data are program to studies look and encouraged early at forward in from the scientific presenting
on other We and excited new advancing be trial design additional we this will time. at program, information provide to the appropriate are and details the
we're we sheet. expand also on clinical programs pipeline, of focused and the our our As balance prudent advance our management keenly therapeutic
our us first believe development with into As on studies Greg complete remain ended we with class programs this and later new clinical the quarter record to in disorders. track the our noted we and/or programs, ongoing advance of in provides our leader to earlier, and existing cash. XXX metabolic treatment We in in therapeutics focused to company million the of the well In development. third best conclusion, advance and clinical believe value establishes a stage opportunities the and class we as create field, the as clinical We endocrine our as well resources continue approximately for clinicians for patients, explore investors.
in from the data complete to report for program NASH of fibrosis and VOYAGE the and expect and we evaluating is lead IIb study this initial VKXXXX enrollment Our XXXX. progressing treatment study through Phase
Our second this ongoing complete study myelin in in Phase of neuropathy, clinical candidate adrenal patients to an Ib expect with is XXXX. treatment in we the VKXXXX, for X-ALD and study
our a of we dual to earlier in which GLP-X agonist expand Finally, this as a have series our and initial efforts models. novel preclinical the announced internal shown week, promise receptors, result GIP from pipeline, results of the of
expect initiate and from This for We today. for Operator? this of a again the questions. prepared compound Thanks development joining now concludes in for we'll series coming clinical lead months. to comments the open us, our call
